Ezatiostat

Drug Profile

Ezatiostat

Alternative Names: Ezatiostat HCl; Ezatiostat hydrochloride; Telintra; TLK-199

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator Telik
  • Developer MabVax Therapeutics; Telik
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glutathione S-transferase pi inhibitors; JNK mitogen-activated protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Myelodysplastic syndromes; Neutropenia

Most Recent Events

  • 25 Aug 2015 No recent reports of development identified - Phase-II for Neutropenia in USA (PO)
  • 25 Aug 2015 No recent reports of development identified - Phase-I for Myelodysplastic syndromes (Combination therapy) in USA (PO)
  • 25 Aug 2015 No recent reports of development identified - Phase-II for Myelodysplastic syndromes (Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top